Decision-making for PCV in adults

Figures & data

Figure 1. Impact of excluding patients with healthcare-associated community-acquired pneumonia (HCAP) and immunocompromising conditions on incidence rates of hospitalized community-acquired pneumonia (per 100,000 person-years) in previously-conducted prospective surveillance studies.^25–27

EPIC = Etiology of Pneumonia in the Community; HCAP = healthcare-associated community-acquired pneumonia.

Figure 2. Potential impact* of PCV13 use in US adults aged ≥ 65 years51.

CAP = community-acquired pneumonia; US = United States; VE = vaccine effectiveness. *assumes 5% all-cause mortality each year and 100% vaccine uptake. ^†A significant effect on all-cause mortality was not demonstrated in Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA).¹⁹

Figure 3. Percentage of hospitalized CAP caused by PCV13 serotypes and percentage that have received PCV13 over time among adults

aged ≥ 65 years, October 2013−September 2016 (n = 6347) ACIP = Advisory Committee on Immunization Practices. CAP = community-acquired pneumonia. PCV13 = 13-valent pneumococcal conjugate vaccine. *Y-axis does not go to 100%. ^†Recommendation for routine use of PCV13 for all adults aged ≥ 65 years.¹⁴

Figure 4. Percentage of hospitalized CAP caused by PCV13 serotypes and percentage that have received PCV13 over time among adults aged 18 to 64 years with “at-risk” conditions, October 2013 to September 2016 (n = 2976) ACIP = Advisory Committee on Immunization Practices. CAP = community-acquired pneumonia. PCV13 = 13-valent pneumococcal conjugate vaccine. “At-risk” patients were defined as the absence of immunocompromising conditions but the presence of ≥ 1 chronic medical condition including: congestive heart failure, diabetes mellitus, chronic obstructive pulmonary disease (COPD), asthma, liver disease, or current alcoholism or smoking. *Y-axis does not go to 100%. ^†Recommendation for routine use of PCV13 for all adults aged ≥ 65 years.¹⁴

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427. doi:10.1056/NEJMoa1500245.

 PubMed Web of Science ®Google Scholar

Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65:1806–1812. doi:10.1093/cid/cix647.

 PubMed Web of Science ®Google Scholar

McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018 Oct 30;67(10):1498–1506. doi:10.1093/cid/ciy312.

 Web of Science ®Google Scholar

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125. doi:10.1056/NEJMoa1408544.

 PubMed Web of Science ®Google Scholar

Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG,Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP). Mmwr. 2014;63:822–825.

 PubMed Web of Science ®Google Scholar